Sensitive method to detect non-complement-fixing antibodies to Epstein-Barr virus nuclear antigne

Area of Science:

• Virology
• Immunology
• Serology

Background:

• Epstein-Barr virus (EBV) infection, commonly known as infectious mononucleosis (IM), is diagnosed using serological tests.
• Standard anti-complement immunofluorescence (ACIF) tests detect complement-fixing antibodies to EBV nuclear antigen (EBNA).
• However, non-complement-fixing EBNA antibodies, particularly IgA and IgG, appear early in IM and are missed by ACIF.

Purpose of the Study:

• To develop and validate a modified ACIF test capable of detecting non-complement-fixing EBNA antibodies.
• To assess the diagnostic utility of detecting these early-appearing EBNA antibodies in infectious mononucleosis.

Main Methods:

• The anti-complement immunofluorescence (ACIF) assay was adapted to detect non-complement-fixing antibodies to EBV nuclear antigen (EBNA).
• Anti-human gamma-globulin (AHG) was applied to bind EBNA antibodies before complement addition.
• Complement fixation to AHG indicated the presence of non-complement-fixing EBNA antibodies (IgA and IgG).

Main Results:

• The modified ACIF test successfully detected non-complement-fixing EBNA-specific IgA and IgG antibodies.
• High titers of these antibodies were observed within weeks of IM onset, preceding the appearance of complement-fixing antibodies.
• Anti-EBNA-IgM antibodies were notably absent in IgM fractions from various IM stages.

Conclusions:

• The modified ACIF test provides an effective method for detecting early-appearing, non-complement-fixing EBNA antibodies (IgA, IgG).
• This assay can aid in the rapid serodiagnosis of infectious mononucleosis.
• The absence of Anti-EBNA-IgM antibodies suggests they are not significant during IM.